WebJul 13, 2024 · Cullinan Oncology, Inc. ( CGEM) is a biopharmaceutical company dedicated to creating new standards of care for patients with cancer. We innovate without borders to find the most promising clinic-ready cancer therapies, whether from our own discovery efforts or through exceptional engagement with our academic and industry partners. WebFeb 7, 2024 · Japan-based Taiho Pharmaceutical has signed an agreement to licence its epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor candidate TAS6417 for …
Taiho and Cullinan renegotiate rights to lung cancer candidate
WebJan 17, 2024 · Press Releases Taiho Oncology, Inc. View a list Taiho Oncology press releases here, sorted by date. Skip to main content Taiho Worldwide Investors Partnering Media CONTACT US ABOUT US Leadership Team Social Responsibility OUR SCIENCE Research & Development Pipeline WebMar 2, 2024 · Adult patients with advanced solid cancers enrolled in the Gustave Roussy Cancer Profiling study (ClinicalTrials.gov identifier: NCT04932525) underwent at least one liquid biopsy (FoundationOne Liquid CDx). Molecular reports were discussed within the Gustave Roussy Molecular Tumor Board (MTB). shohag bus ticket
Cullinan Oncology and Taiho Pharmaceutical Announce …
WebTaiho Oncology, Inc. is focused on bringing novel technology to cornerstone chemotherapies for a wide range of tumor types-including colorectal cancer and a variety of solid tumors. Learn More Features … WebDec 5, 2024 · Taiho and Cullinan renegotiate rights to lung cancer candidate 12-05-2024 Print Tokyo’s Taiho Pharmaceutical, a business of Japanese drug major Otsuka Pharmaceutical (TYO: 4768), has agreed to buy part of Cullinan Oncology (Nasdaq: CGEM), thereby regaining rights to a candidate it out-licensed in 2024. WebMay 12, 2024 · Cullinan Oncology will receive an upfront cash payment of $275 million, with potential to receive up to an additional $130 million in regulatory-based milestone … shohag elite bus